drugset / Trial / NCT03823911
Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication
Phase 4
Completed
87 enrolled
University of Maryland, Baltimore
Merck Sharp & Dohme LLC · collabNational Institutes of Health (NIH) · collab
Non-randomizedParallel-groupOpen-labelBasic science
Summary
This is an interventional, non-randomized, controlled prospective study to treat HCV in mono-infected and HIV co-infected individuals and compare cardiovascular risk outcomes to HIV mono-infected controls. This pilot study will demonstrate whether functional cure of HCV reduces myocardial injury and risk of cardiovascular disease.
Timeline
- Start
- 2018-11-18
- Primary completion
- 2022-12-31
- Completion
- 2022-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Elbasvir / Grazoprevir | Unknown | — | Oral |